Description

In vitro Proof-of-Principle

Heparan sulfate and heparin play a central role in a large number of processes including angiogenesis, anti-coagulation, cell growth and migration. Short oligosaccharides which block angiogenesis through inhibition of heparin sulphate-dependent growth factor signalling have been discovered. Efficacy has been demonstrated in vivo with partially-purified preparations and in vitro with synthetic oligosaccharides. Optimisation of the oligosaccharides is ongoing. A scalable synthesis route has been developed and optimised. CRT is now seeking a commercial partner to progress this programme under a licensing or co-development model.

For more information please contact

Dr Martyn Bottomley

+44 (0) 20 3469 6300 .(JavaScript must be enabled to view this email address)